BridgeBio Up 10% After FDA Fast Track

BridgeBio Oncology Therapeutics shares jumped about 10% in after‑hours trading after FDA’s Fast Track designation for BBO‑11818.
The Fast Track status aims to speed development of the pan‑KRAS inhibitor targeting advanced KRAS‑mutant pancreatic ductal adenocarcinoma.
Preliminary January 2026 data showed BBO‑11818 monotherapy achieved confirmed partial responses and tumor reductions at higher dose levels.
KRASG12D and KRASG12V mutations lack effective therapies, making BBO‑11818’s pan‑KRAS approach clinically significant.